Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab govitecan versus standard of care in previously treated extensive-stage small cell lung cancer
2024-515884-69-00Phase 3Authorised
- Sponsor
- Gilead Sciences
- Start
- Jul 2025
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial in small cell lung cancer (SCLC) comparing Sacituzumab govitecan with Standard of care topotecan (2 arms). Primary endpoint: Overall survival. Planned start Jul 2025; status: authorised.
02
Drugs
sacituzumab govitecantopotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2024-515884-69-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515884-69-00.